We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]

BISPHOSPHONATES The most common family of drugs used to treat osteoporosis Bisphosphonates are the most common family of drugs used to treat osteoporosis. They are part of the group of […]

A recently released Canadian research study confirms what has been shown in past preliminary studies; – inflammation of the eye as a possible side effect of bisphosphonate therapy is very […]

We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]

PROVINCIAL DRUG COVERAGE AS OF FEBRUARY 2024 Coverage is under constant review and is subject to change. Access to a generic equivalent is generally reported to be identical to that […]

A recently released Canadian research study confirms what has been shown in past preliminary studies; – inflammation of the eye as a possible side effect of bisphosphonate therapy is very […]

We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]

Osteoporosis is a chronic condition that, if you are at high risk of fracture, requires treatment with an osteoporosis medication. There is currently no evidence that osteoporosis medications increase the […]

Dr. Aliya Khan, Dr. Heather Frame, Dr. Claudia Gagnon, Dr. Rowena Ridout, Dr. Lianne Tile and Dr. Sandra Kim Recommendations from Osteoporosis Canada Rapid Response Team Osteoporosis is a chronic […]